OncoMatch/Clinical Trials/NCT04702581
A Randomized Trial of Delayed Radiotherapy in Patients Low-grade Oligodendrogliomas Requiring a Treatment Other Than Surgery
Is NCT04702581 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including PCV chemotherapy and Radiotherapy and PCV chemotherapy for oligodendroglioma.
Treatment: PCV chemotherapy · Radiotherapy and PCV chemotherapy — Because of their prolonged survival, patients with 1p/19q-codeleted low-grade oligodendrogliomas treated with RT + PCV are at risk of neurocognitive deterioration. We make the hypothesis that withholding radiotherapy until tumor progression could reduce the risk of neurocognitive deterioration without impairing overall survival.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 mutation
IDH-mutant (IDH1 or IDH2) according to local diagnosis
Required: IDH2 mutation
IDH-mutant (IDH1 or IDH2) according to local diagnosis
Required: 1P deletion
Tumor is co-deleted for 1p and 19q
Required: 19Q deletion
Tumor is co-deleted for 1p and 19q
Disease stage
Grade: low-grade (WHO 2016)
Histological confirmation of low-grade oligodendroglioma by central pathological review according to WHO 2016 classification
Prior therapy
Cannot have received: radiation therapy
Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
Cannot have received: chemotherapy
Received any prior radiation therapy or chemotherapy for any CNS neoplasm.
Lab requirements
Blood counts
anc ≥1500 /mm3; platelet count ≥100,000 / mm3; hemoglobin > 9.0 g/dl
Liver function
total bilirubin ≤ 1.5 x uln; sgot (ast) ≤ 3 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify